Late Breaking Abstract Parallel Session 1

Nov 10 2025
Convention Center: Hall A (General Session), Concourse Level
2:00 PM - 3:30 PM
Live Streamed
Captured

World Class Speakers

Mazen Noureddin
Abstract Presenter

Mazen Noureddin

Houston Research Institute and Houston Methodist Hospital
Neehar D. Parikh, MD, MS, FAASLD
Abstract Presenter

Neehar D. Parikh, MD, MS, FAASLD

University of Michigan Medical Center
Jörn M Schattenberg, MD
Abstract Presenter

Jörn M Schattenberg, MD

Saarland University Medical Center Homburg
Rotonya M. Carr, MD, FACP, FAASLD
Moderator

Rotonya M. Carr, MD, FACP, FAASLD

University of Washington
Debbie L Shawcross, BSc, MBBS, PhD, FRCP
Moderator

Debbie L Shawcross, BSc, MBBS, PhD, FRCP

Roger Williams Institute of Liver Studies

Description

Late-Breaking Abstract Parallel sessions feature oral presentations from the authors of cutting-edge, highly-rated abstracts submitted for presentation at The Liver Meeting.

Presentations

2:00 PM - 2:15 PM
Aug 06 2026
Convention Center - Hall A (General Session), Concourse Level

HU6 Oral Investigational Therapy Reduces Liver Fat and Improves Adiposity Markers in Adults with MASH: Topline Results from a Phase 2 Randomized Placebo-Controlled Trial (M-ACCEL)

Mazen Noureddin , Abstract Presenter
2:15 PM - 2:30 PM
Aug 06 2026
Convention Center - Hall A (General Session), Concourse Level

A Blood-Based Combined Methylation and AFP Test for Early Detection of Hepatocellular Carcinoma in At-Risk Population: Validation and Performance

Neehar D. Parikh, MD, MS, FAASLD , Abstract Presenter
2:30 PM - 2:45 PM
Aug 06 2026
Convention Center - Hall A (General Session), Concourse Level

Long-term treatment with elafibranor leads to biochemical and symptomatic improvements for at least 3 years in patients with primary biliary cholangitis

Jörn M Schattenberg, MD , Abstract Presenter
3:15 PM - 3:30 PM
Aug 06 2026
Convention Center - Hall A (General Session), Concourse Level

Top-Line Phase 2 Results of DD01, a Dual GLP-1/Glucagon Agonist, Lead to Rapid Improvements in Liver and Metabolic Endpoints in Patients with MASLD/MASH

Mazen Noureddin , Abstract Presenter

Objectives

  • Discuss cutting-edge research into a variety of liver-related conditions, including MASLD/MASH, HCC, and PBC.